Trials / Completed
CompletedNCT01520246
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
Signaling in Tumorigenesis and Immunity
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.
Detailed description
OBJECTIVES: * To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as control. OUTLINE: Previously collected cancer and control tissues are analyzed for the expression patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also co-cultured with HTLV-1-transformed T-cell lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | gene expression analysis | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2016-07-01
- First posted
- 2012-01-27
- Last updated
- 2016-07-11
Source: ClinicalTrials.gov record NCT01520246. Inclusion in this directory is not an endorsement.